Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

BACKGROUND: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. METHODS: We calculated costs and quality-adjusted life-years from the UK National Hea...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmacoeconomics
Auteurs principaux: Pennington, Becky, Alshreef, Abualbishr, Flight, Laura, Metry, Andrew, Poku, Edith, Hykin, Philip, Sivaprasad, Sobha, Prevost, A. Toby, Vasconcelos, Joana C., Murphy, Caroline, Kelly, Joanna, Yang, Yit, Lotery, Andrew, Williams, Michael, Brazier, John
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2021
Sujets:
Original Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298346/
https://ncbi.nlm.nih.gov/pubmed/33900585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-021-01026-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires